HLN Stock Overview
Engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 2/6 |
| Financial Health | 2/6 |
| Dividends | 2/6 |
Haleon plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£3.72 |
| 52 Week High | UK£4.01 |
| 52 Week Low | UK£3.08 |
| Beta | 0.24 |
| 11 Month Change | -0.98% |
| 3 Month Change | 0.30% |
| 1 Year Change | 12.81% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 20.77% |
Recent News & Updates
Haleon plc Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Nov 03
Calculating The Fair Value Of Haleon plc (LON:HLN)
Nov 01Is Haleon (LON:HLN) Using Too Much Debt?
Oct 11Recent updates
Haleon plc Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Nov 03Calculating The Fair Value Of Haleon plc (LON:HLN)
Nov 01Is Haleon (LON:HLN) Using Too Much Debt?
Oct 11Haleon (LON:HLN) Might Have The Makings Of A Multi-Bagger
Sep 06Estimating The Fair Value Of Haleon plc (LON:HLN)
Jun 26Haleon plc Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
May 04Haleon plc's (LON:HLN) Popularity With Investors Is Clear
Mar 06Calculating The Intrinsic Value Of Haleon plc (LON:HLN)
Jan 21Haleon (LON:HLN) Might Have The Makings Of A Multi-Bagger
Nov 24Estimating The Intrinsic Value Of Haleon plc (LON:HLN)
Sep 10Haleon (LON:HLN) Shareholders Will Want The ROCE Trajectory To Continue
Aug 14Haleon plc's (LON:HLN) Intrinsic Value Is Potentially 23% Below Its Share Price
May 03Haleon plc Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Mar 22Investors Can Find Comfort In Haleon's (LON:HLN) Earnings Quality
Mar 10Calculating The Fair Value Of Haleon plc (LON:HLN)
Dec 18Shareholder Returns
| HLN | GB Personal Products | GB Market | |
|---|---|---|---|
| 7D | 2.9% | 1.1% | 0.7% |
| 1Y | 12.8% | 17.0% | 6.1% |
Return vs Industry: HLN underperformed the UK Personal Products industry which returned 17% over the past year.
Return vs Market: HLN exceeded the UK Market which returned 6.1% over the past year.
Price Volatility
| HLN volatility | |
|---|---|
| HLN Average Weekly Movement | 1.9% |
| Personal Products Industry Average Movement | 4.7% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in GB Market | 10.4% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: HLN has not had significant price volatility in the past 3 months compared to the UK market.
Volatility Over Time: HLN's weekly volatility (2%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1715 | 25,408 | Brian McNamara | www.haleon.com |
Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands. It also offers various over-the-counter products comprising nasal drops, and cold, flu, and allergy relief products under Otrivine, Theraflu, and Flonase brands for respiratory issues; anti-inflammatory and pain relief products under Voltaren, Panadol, and Advil brands; and antacids and antihistamine products under TUMS, ENO, and Fenistil brands for digestive health and other issues.
Haleon plc Fundamentals Summary
| HLN fundamental statistics | |
|---|---|
| Market cap | UK£33.37b |
| Earnings (TTM) | UK£1.21b |
| Revenue (TTM) | UK£11.24b |
27.9x
P/E Ratio3.0x
P/S RatioIs HLN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HLN income statement (TTM) | |
|---|---|
| Revenue | UK£11.24b |
| Cost of Revenue | UK£4.25b |
| Gross Profit | UK£6.99b |
| Other Expenses | UK£5.78b |
| Earnings | UK£1.21b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 27, 2025
| Earnings per share (EPS) | 0.13 |
| Gross Margin | 62.20% |
| Net Profit Margin | 10.75% |
| Debt/Equity Ratio | 54.2% |
How did HLN perform over the long term?
See historical performance and comparison